EX-23.1 6 exhibit_23-1.htm EXHIBIT 23.1

Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Chemomab Therapeutics Ltd.:
We consent to the use of our report dated February 20, 2023, with respect to the consolidated financial statements of Chemomab Therapeutics Ltd., included herein and to the reference to our firm under the heading “Experts” in the prospectus.
Somekh Chaikin
Member Firm of KPMG International
Tel Aviv, Israel
February 21, 2023